BioCryst Pharmaceuticals, Inc. (BCRX) — Estimates & Forecasts
Proprietary EPS, revenue & margin forecasts — FY+1 to FY+4
Popular:
Proprietary EPS, revenue & margin forecasts — FY+1 to FY+4
| Metric | 2023 | 2024 | 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|
| Net Income | $-227M | $-89M | $264M | $405M | $687M | $1.1B | $1.6B |
| EPS (Diluted) | $-1.18 | $-0.43 | $1.21 | $1.75 | $2.81 | $4.41 | $5.69 |
| YoY Growth | — | — | — | +53.3% | +69.8% | +66.1% | +36.2% |
| Net Margin | -68.4% | -19.7% | 30.2% | 33.3% | 38.5% | 44.1% | 47.9% |
| Metric | 2025A | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|
| Revenue | $875M | $1.2B | $1.8B | $2.6B | $3.2B |
| Net Income | $264M | $405M | $687M | $1.1B | $1.6B |
| EPS (Diluted) | $1.21 | $1.75 | $2.81 | $4.41 | $5.69 |
| Free Cash Flow | $347M | $325M | $540M | $865M | $1.2B |
Treat point estimates cautiously; use wider scenario ranges and position sizing discipline.
BioCryst Pharmaceuticals, Inc.'s projected EPS for the next fiscal year is $1.75. This estimate blends our quantitative model with Wall Street analyst consensus and carries a confidence score of 28/100. The model factors in revenue trajectory, margin path, and share buyback trends to arrive at this figure.
Our scenario-based model produces three price targets for BioCryst Pharmaceuticals, Inc.: Bear case $-1435, Base case $20, and Bull case $177. These targets are derived by applying the median historical P/E ratio to forward EPS estimates under each growth scenario. They are not buy/sell recommendations.
BioCryst Pharmaceuticals, Inc.'s projected revenue growth for the next fiscal year is 38.7%, reaching approximately $1.2B in total revenue. Growth estimates are probability-weighted and blend analyst consensus with our CAGR extrapolation model. Outer years (FY+3, FY+4) fade toward industry median growth rates.
Accuracy depends on several measurable factors. Our model confidence score of 28/100 is computed from revenue predictability (25% weight), margin stability (20%), historical earnings beat rate (20%), data depth (15%), analyst coverage (10%), and model-consensus agreement (10%). Currently expanding margins support higher forecast reliability. No forecast model is perfect — always cross-reference with your own analysis.
BioCryst Pharmaceuticals, Inc.'s forward operating margin is estimated at 44.8% for the next fiscal year. The margin trend is currently "expanding". Our model tracks margin mean-reversion patterns and adjusts for sector-specific cost dynamics. Operating leverage is a key driver of EPS growth beyond top-line revenue expansion.
The v2 model uses a multi-step process: (1) Revenue is projected via blended CAGR with probability weighting, (2) Operating and net margins follow a mean-reversion path calibrated to sector norms, (3) EPS is derived from net income divided by projected diluted shares (accounting for buyback trends), (4) For FY+1 and FY+2, estimates are blended with analyst consensus based on coverage depth, (5) Price targets apply median historical P/E to forward EPS under bear/base/bull growth scenarios. All inputs are from public filings and third-party data providers.
The bear case ($-1435) assumes P25 revenue growth, worst-case margins, and multiple compression. Key risks include: unexpected margin contraction, revenue deceleration below model floor, regulatory headwinds, macro deterioration, or competitive disruption. A confidence score below 60 suggests higher estimate volatility. Always size positions according to the full scenario range, not just the base case.
Our model is above Wall Street consensus with a 462.3% gap. For FY+1, analyst estimates blend with our model at 15% analyst weight. By FY+3 and FY+4, estimates are purely model-driven as analyst coverage thins out at longer horizons.